#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Cardiac amyloidosis KBG syndrome B-cell small lymphocytic lymphoma recurrent Systemic scleroderma Neurotrophic keratopathy Chronic lymphocytic leukaemia refractory Deafness bilateral Crohn's disease Sexually transmitted disease Vulval cancer Oropharyngeal squamous cell carcinoma HER2 mutant non-small cell lung cancer Vascular malformation Glycogen storage disease type II Neuronal ceroid lipofuscinosis More trials…

    Learn about Rare Diseases

    Rhabdomyosarcoma recurrent – Trials in Disease Brain stem glioma – Basic Information Hypereosinophilic syndrome – Trials in Disease Behcet’s syndrome – Basic Information Amyotrophic lateral sclerosis – Trials in Disease Hereditary angioedema – Treatment Myxofibrosarcoma Haemophilia A with anti factor VIII – Treatment Bronchopulmonary dysplasia – Basic Information Systemic mastocytosis – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Urokinase Anhydrous Caffeine Amantadine Hydrochloride Tetracosactide PICLIDENOSON ABBV-CLS-628 Ofloxacin Nimorazole OMEGA-3-ACID ETHYL ESTERS 90 Ciclosporin Dabrafenib Mesylate Gad20-209-Fsp-A4 Eprosartan Mesilate Aliskiren Etoposide Phosphate Eribulin Mesylate Lanifibranor Gozetotide Rilzabrutinib Ro7589655 More therapies…

    Learn about Your Condition

    Incisional hernia Aicardi-Goutieres syndrome Vascular dementia Metastatic glioma Dyspepsia Glomerulonephritis acute Pancreatic carcinoma stage IV Retinal artery occlusion Psoriatic arthropathy Erosive oesophagitis Neurofibromatosis BK virus infection Follicular lymphoma stage IV Pulmonary alveolar haemorrhage Drug use disorder More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Crohn’s disease

  • Study of Mirikizumab for Children and Teens with Moderate-to-Severe Ulcerative Colitis or Crohn’s Disease

    Recruiting

    3 1 1
    Investigated Diseases:
    • Crohn’s disease
    • Colitis ulcerative
    Investigated Drugs:
    • Mirikizumab
    Austria Belgium France Germany Italy The Netherlands +4

  • Study Comparing Vedolizumab and Adalimumab for Crohn’s Disease Patients Who No Longer Respond to Adalimumab

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • Vedolizumab
    • Adalimumab
    France

  • Study on Crohn’s Disease: Evaluating Risankizumab’s Effects in Children Aged 2 to 17 with Moderate to Severe Symptoms

    Recruiting

    3 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • Risankizumab
    Belgium Bulgaria Czechia France Germany Italy +4

  • Study on Preventing Crohn’s Disease Recurrence After Surgery Using Risankizumab and Drug Combination in Adults at Risk

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • Vedolizumab
    • Mirikizumab
    • Risankizumab
    Belgium Italy

  • Study on INTESTIFIX for Maintaining Remission in Children and Adults with Crohn’s Disease After Exclusive Enteral Nutrition Treatment

    Recruiting

    1 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • Intestifix
    Germany

  • Study on Gallium (68Ga) Chloride for Early Healing of Perianal Crohn’s Disease Fistulas in Patients

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Anal fistula
    • Crohn’s disease
    Investigated Drugs:
    • Gallium (68Ga) Chloride
    The Netherlands
Previous Page
1 … 6 7 8 9 10 … 16
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!